ECSP066663A - Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso - Google Patents

Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso

Info

Publication number
ECSP066663A
ECSP066663A EC2006006663A ECSP066663A ECSP066663A EC SP066663 A ECSP066663 A EC SP066663A EC 2006006663 A EC2006006663 A EC 2006006663A EC SP066663 A ECSP066663 A EC SP066663A EC SP066663 A ECSP066663 A EC SP066663A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical composition
parenteral administration
preparation process
vinflunine
vinflunine pharmaceutical
Prior art date
Application number
EC2006006663A
Other languages
English (en)
Inventor
Elie Leverd
Joel Bougaret
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34630533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066663(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of ECSP066663A publication Critical patent/ECSP066663A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica de vinflunina en forma de una solución acuosa estable y estéril de una sal de vinflunina soluble en agua, a un pH de entre 3 y 4. La invención además se refiere al proceso para la preparación de esta composición, y a su uso como una especialidad medicinal para administración parenteral, en el tratamiento de cáncer.
EC2006006663A 2003-12-23 2006-06-21 Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso ECSP066663A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0315312A FR2863891B1 (fr) 2003-12-23 2003-12-23 Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation

Publications (1)

Publication Number Publication Date
ECSP066663A true ECSP066663A (es) 2006-10-25

Family

ID=34630533

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006663A ECSP066663A (es) 2003-12-23 2006-06-21 Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso

Country Status (34)

Country Link
US (1) US20070155768A1 (es)
EP (1) EP1696913B1 (es)
JP (2) JP5226220B2 (es)
KR (1) KR101166347B1 (es)
CN (2) CN101695474A (es)
AR (1) AR047346A1 (es)
AT (1) ATE424201T1 (es)
AU (1) AU2004314154B2 (es)
BR (1) BRPI0418005B8 (es)
CA (1) CA2551493C (es)
CR (1) CR8473A (es)
CY (1) CY1109120T1 (es)
DE (1) DE602004019809D1 (es)
DK (1) DK1696913T3 (es)
EC (1) ECSP066663A (es)
ES (1) ES2323374T3 (es)
FR (1) FR2863891B1 (es)
IL (1) IL176404A (es)
MA (1) MA28237A1 (es)
MX (1) MXPA06007208A (es)
MY (1) MY139643A (es)
NI (1) NI200600146A (es)
NO (1) NO336427B1 (es)
NZ (1) NZ548028A (es)
OA (1) OA13348A (es)
PL (1) PL1696913T3 (es)
PT (1) PT1696913E (es)
RU (1) RU2362557C2 (es)
SI (1) SI1696913T1 (es)
TN (1) TNSN06197A1 (es)
TW (1) TWI334352B (es)
UA (1) UA83888C2 (es)
WO (1) WO2005070425A1 (es)
ZA (1) ZA200605201B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation
US20110015221A1 (en) * 2003-12-23 2011-01-20 Pierre Fabre Medicament Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same
FR2910812B1 (fr) * 2006-12-29 2009-03-20 Pierre Fabre Medicament Sa Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante
FR2912406B1 (fr) * 2007-02-13 2009-05-08 Pierre Fabre Medicament Sa Sels cristalins anhydres de vinflunine, procede de preparation et utilisation en tant que medicament et moyen de purification de la vinflunine.
EP1997534A1 (en) * 2007-05-31 2008-12-03 Pierre Fabre Medicament Cancer treatment combination therapy comprising vinflunine and trastuzumab
CN101129374B (zh) * 2007-06-26 2010-09-08 齐鲁制药有限公司 长春氟宁药物组合物及其制备方法与应用
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
FR2918566B1 (fr) * 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
CN101607968A (zh) * 2008-06-17 2009-12-23 江苏豪森药业股份有限公司 长春氟宁盐、其制备方法及其药物组合物
SG193932A1 (en) * 2011-03-29 2013-11-29 Sanofi Sa Otamixaban formulations with improved stability
US11058679B2 (en) * 2015-08-01 2021-07-13 Sun Pharmaceutical Industries Ltd. Dosage form of vinca alkaloid drug
WO2018007554A1 (en) * 2016-07-06 2018-01-11 Pierre Fabre Medicament Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307100A (en) * 1978-08-24 1981-12-22 Agence Nationale De Valorisation De La Recherche (Anvar) Nor bis-indole compounds usable as medicaments
US4619935A (en) * 1983-03-17 1986-10-28 Eli Lilly And Company Stable oncolytic formulations
HU195513B (en) * 1984-10-16 1988-05-30 Richter Gedeon Vegyeszet Process for producing stable solutions of alkaloides with bis-indole skeleton
FR2597750B1 (fr) * 1986-04-25 1989-06-02 Pf Medicament Solution aqueuse stable de sulfate de vincristine
IL83086A (en) * 1987-07-06 1991-03-10 Teva Pharma Stable,injectable solutions of vincristine salts
US4923876A (en) * 1988-04-18 1990-05-08 Cetus Corporation Vinca alkaloid pharmaceutical compositions
CA2001643A1 (en) * 1988-12-23 1990-06-23 Richard L. Wolgemuth Preservative-free multi-dose vincristine solution
HU204995B (en) * 1989-11-07 1992-03-30 Richter Gedeon Vegyeszet Process for producing pharmaceutical composition comprising alkaloid with bis-indole skeleton, with antitumour activity and suitable fr parenteral purposes
JPH06100452A (ja) * 1993-04-06 1994-04-12 Asta Medica Ag イホスファミド用の製薬学的容器
FR2707988B1 (fr) * 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
DE19706255C2 (de) * 1997-02-18 2000-11-30 Schott Glas Sterilisierbarer Glasbehälter für medizinische Zwecke, insbesondere zur Aufbewahrung pharmazeutischer oder diagnostischer Produkte
FR2761990B1 (fr) * 1997-04-10 1999-06-25 Pf Medicament Derives halogenes antimitotiques d'alcaloides de vinca
JP3642492B1 (ja) * 2003-10-31 2005-04-27 小野薬品工業株式会社 オザグレルナトリウム含有水溶液を充填してなる注射用容器
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation

Also Published As

Publication number Publication date
US20070155768A1 (en) 2007-07-05
KR20060124624A (ko) 2006-12-05
DK1696913T3 (da) 2009-06-29
ES2323374T3 (es) 2009-07-14
TW200531717A (en) 2005-10-01
AR047346A1 (es) 2006-01-18
RU2362557C2 (ru) 2009-07-27
NI200600146A (es) 2006-12-12
RU2006126708A (ru) 2008-01-27
CY1109120T1 (el) 2014-07-02
TNSN06197A1 (fr) 2007-11-15
TWI334352B (en) 2010-12-11
UA83888C2 (ru) 2008-08-26
AU2004314154A1 (en) 2005-08-04
ZA200605201B (en) 2007-09-26
FR2863891B1 (fr) 2006-03-24
ATE424201T1 (de) 2009-03-15
NO336427B1 (no) 2015-08-17
JP2012102120A (ja) 2012-05-31
SI1696913T1 (sl) 2009-08-31
JP5710462B2 (ja) 2015-04-30
KR101166347B1 (ko) 2012-07-18
WO2005070425A1 (fr) 2005-08-04
OA13348A (fr) 2007-04-13
EP1696913A1 (fr) 2006-09-06
NZ548028A (en) 2010-01-29
CN101695474A (zh) 2010-04-21
CN1897940A (zh) 2007-01-17
JP5226220B2 (ja) 2013-07-03
DE602004019809D1 (de) 2009-04-16
NO20063277L (no) 2006-07-14
AU2004314154B2 (en) 2011-03-24
PT1696913E (pt) 2009-06-05
MY139643A (en) 2009-10-30
MA28237A1 (fr) 2006-10-02
BRPI0418005B1 (pt) 2019-11-26
EP1696913B1 (fr) 2009-03-04
FR2863891A1 (fr) 2005-06-24
IL176404A0 (en) 2006-10-05
MXPA06007208A (es) 2006-08-18
JP2007515461A (ja) 2007-06-14
BRPI0418005A (pt) 2007-04-17
BRPI0418005B8 (pt) 2021-05-25
CR8473A (es) 2006-11-24
HK1089105A1 (zh) 2006-11-24
CA2551493C (fr) 2012-12-04
CA2551493A1 (fr) 2005-08-04
PL1696913T3 (pl) 2009-08-31
IL176404A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
EP4458896A3 (en) Bioorthogonal compositions
BRPI0608853B8 (pt) composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes
CY1109120T1 (el) Φαρμακευτικη συνθεση βινφλουνινης που προοριζεται για παρεντερικη χορηγηση, μεθοδος παρασκευης και χρησης
TW200500067A (en) Salts of codrugs and uses related thereto
UA91512C2 (ru) Коньюгати олигомеров инсулина, их композиция (варианты) и применение
BRPI0608297A2 (pt) composições de lipossomos
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
TW200505924A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
UA105210C2 (ru) Противораковая вакцина и ее применение
WO2005097135A3 (en) Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives
CU23367A3 (es) Formulación de moxifloxacino con sal común
WO2005072061A3 (en) Conjugates for cancer therapy and diagnosis
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
TNSN07419A1 (en) Methods for treating drug resistant cancer
WO2006029081A3 (en) Nucleoside-lipid conjugates, their method of preparation and uses thereof
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
BRPI0411702B8 (pt) uso de ácido hialurônico para preparar composições para o tratamento de aftas da cavidade oral
PE20050189A1 (es) Composiciones que comprenden derivados de acido quinoloncarboxilico para administracion local
WO2008051527A3 (en) Sustained release of agents for localized pain management
BRPI0513287A (pt) derivados de pirido-pirimidina, sua preparação, sua aplicação em terapêutica
WO2006131923A3 (en) Novel salts of conjugated psychotropic drugs and processes of preparing same
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
UA88884C2 (ru) Набор для приготовления фармацевтических композиций цис-оксоплатина, фармацевтическая композиция и ее применение при лечении рака